12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kcentra 4-factor prothrombin complex concentrate regulatory update

CSL said FDA approved a label expansion for Kcentra to include the urgent reversal of anticoagulation with vitamin K antagonist therapy, including warfarin,...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >